Navigation Links
Blockbuster Expectations Don't Always Translate to Market Reality

LONDON and BOSTON, April 9, 2013 /PRNewswire/ --

EP Vantage Analyzes Accuracy of Analyst Sales Estimates for Blockbuster and Near-Blockbuster Launches

Pharma industry observers widely expect Biogen Idec's new multiple sclerosis therapy Tecfidera to reach mega-blockbuster status. However, EP Vantage®, EvaluatePharma®'s award-winning editorial team cautions that forecasting revenue for an unlaunched drug isn't always easy. A five-year review of EvaluatePharma's consensus forecasts of analyst predictions for blockbuster or near-blockbuster drug launches found that new products with the biggest hopes often disappoint, while others have vastly outperformed low expectations.

The report, "The Industry's Brightest Hopes: Where Are They Now?" uncovers some remarkable misses prompted by a sea change in treatment, reimbursement issues, safety concerns and heightened competition. While analysts' forecasts don't always ring true on performance, EP Vantage found that forecasts have also been spot on and in some cases performances even exceeded initial estimates.

"Evaluating the accuracy of consensus forecasts is particularly pertinent given the recent US approval of Tecfidera, with consensus data suggesting that this drug's sales could reach $3.7 billion within five years. Many factors can influence the success of a drug and while forecasts have been proven to ring true in many cases, our analysis shows just how far off they can be," commented Jacob Plieth , author of the EP Vantage report.

As the first company to provide consensus forecasts on global drug sales, EvaluatePharma takes the unweighted average of up to six equity research forecasts to provide reliable consensus estimates for the pharma and biotech industries to 2018. By taking an average, the impact of outlying forecasts is mitigated.

For a look at which of 2013's launches will be the next blockbusters, read the analysis here.

About EP Vantage

Written by a team of award winning pharma journalists, EP Vantage provides daily financial analysis of key industry catalysts including: regulatory and patent decisions, marketing approvals, licensing deals, and M&A - giving fresh angles and insight to both current and future industry triggers.

Launched in 2007 by EvaluatePharma, EP Vantage's unique access to EvaluatePharma data allows unrivaled, forward-looking, coverage of the pharmaceutical and biotech industry.

To register for a free trial of EP Vantage please visit:

About Evaluate Ltd.

Since 1996, EvaluatePharma has been the premier source for high quality life science sector analysis, delivering exclusive consensus forecasts and trusted commercial insight into biotech and pharmaceutical performance. EvaluateMedTech sets a new standard in integrated analysis and consensus forecasts of the global medical device and diagnostic industry. EvaluateClinical Trials delivers unique intelligence to efficiently and accurately analyze the global clinical trial landscape.  A team of over 85 dedicated healthcare analysts employ rigorous methodologies to collate, organize and deliver the most-up-to-date commercial performance data available. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit

Media Contacts:
EP Vantage EvaluatePharma
Christine Lindgren

Chempetitive Group (for US media)
Rachel Lear

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
2. Abbott Sued for False Claims Related to its Blockbuster Drug TriCor
3. Area Radiology Groups Brand Makeover Redefines Customer Experience Expectations in Healthcare
4. Fluke Biomedical launches six translated websites
5. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
6. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
7. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
10. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
11. Ophthalmic Drugs: World Market Prospects 2012-2022
Post Your Comments:
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
Breaking Medicine News(10 mins):